Amgen Inc.

Bayer Pharma Aktiengesellschaft

Piramal Imaging Sa

Pharmasol Gmbh

Carsten Olbrich

Bernhard Luy

Matthias Plitzko

Michael Krause

Thomas Bunte

Jörg Peters

Rainer Helmut M&uuml;ller

Annett Richter

Rainer Braun

Jonas Winter

Stefan Christian Schneid

Thomas Trill

Andreas Burkhard

Marieke Veurink

Jorg Peters

The present invention relates to stable pharmaceutical compositions which contain polypeptides having at least two antigen-binding domains and are especially suited for subcutaneous administration. The invention provides liquid compositions which minimize the formation of undesired polypeptide aggregates (dimers and/or multimers). The present invention further provides a method for minimizing the aggregation of polypeptides having antigen-binding domains in liquid compositions.

Formulation for bispecific T-cell engagers (BiTEs)

A method for the production of freeze-dried pellets comprising factor VIII comprises the steps of: a) freezing droplets of a solution comprising factor VIII to form pellets; b) freeze-drying the pellets; wherein in step a) the droplets are formed by means of droplet formation of the solution comprising factor VIII into a cooling tower which has a temperature-controllable inner wall surface and an interior temperature below the freezing temperature of the solution and wherein in step b) the pellets are freeze-dried in a rotating receptacle which is housed inside a vacuum chamber.

Method for the production of freeze-dried pellets comprising factor VIII

The invention is directed to formulations of lipophilic Amyloid beta ligand stilbene and more particularly to formulations which are capable to be administered parenterally e.g. intravenously, wherein the lipophilic Amyloid beta ligand stilbene is a fluorinated stilbene. Further, the invention is directed to a method for sterile filtration of formulations suitable for PET imaging of mammals pursuant to the invention.

Formulations of fluorinated stilbene suitable for PET imaging

The invention relates to particulate active ingredient vehicles which are in the solid aggregate state at room temperature (20&deg; C.) and consist of a pure lipid-drug conjugate (LDC) or a mixture of several LDCs as particle matrix, the bond in the LDC being effected by covalent bonding, electrostatic interactions, dipole moments, dispersion forces, ion interactions, hydrogen bridges and/or hydrophobic interactions.

Lipid matrix-drug conjugates particle for controlled release of active ingredient

Growing community of inventors

Berlin, Germany

Carsten Olbrich